Chemistry and structure-activity relationship of the styrylquinoline-type HIV integrase inhibitors

Molecules

Volumn 15, Issue 5, 2010, Pages 3048-3078

  Mouscadet, Jean François ^a   Desmaële, Didier ^b  

^a Ecole Normale Superieure de Cachan   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

AIDS; HIV 1; Inhibitor; Integrase; Styrylquinoline

Indexed keywords

INTEGRASE INHIBITOR; PROTEIN BINDING; QUINOLINE DERIVATIVE; STYRYLQUINOLINE;

CHEMISTRY; COMPUTER SIMULATION; HUMAN; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

COMPUTER SIMULATION; CRYSTALLOGRAPHY, X-RAY; HIV INTEGRASE INHIBITORS; HUMANS; PROTEIN BINDING; QUINOLINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77952829226     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules15053048     Document Type: Review

References (55)

1. Lalezari, J.P.; Henry, K.; O'Hearn, M.; Montaner, J.S.; Piliero, P.J.; Trottier, B.; Walmsley, S.; Cohen, C.; Kuritzkes, D.R.; Eron, J.J., Jr.; Chung, J.; DeMasi, R.; Donatacci, L.; Drobnes, C.; Delehanty, J.; Salgo, M. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N. Engl. J. Med. 2003, 348, 2175-2185.
2. Stellbrink, H.-J. Novel compounds for the treatment of HIV type-1 infection. Antivir. Chem. Chemother. 2009, 19, 189-200.
3. Hunt, J.S.; Romanelli, F. Maraviroc, a CCR5 coreceptor antagonist that blocks entry of human immunodeficiency virus type 1. Pharmacotherapy 2009, 29, 295-304.
4. Pommier, Y.; Johnson, A.A.; Marchand, C. Integrase inhibitor to treat HIV/AIDS. Nature Rev. Drug Disc. 2005, 4, 236-247.
5. Lewinski, M.K.; Bushman, F.D. Retroviral DNA integration-mechanism and consequences. Adv. Genet. 2005, 55, 147-181.
6. Chirch, L.M.; Morrison, S.; Steigbigel, R.T. Treatment of HIV infection with raltegravir. Expert Opin. Pharmaco. 2009, 10, 1203-1211.
7. Vandeckerckhove L. GSK-1349572, a novel integrase inhibitor for the treatment of HIV infection. Curr. Opin. Investig. Drugs 2010, 11, 203-212.
8. Katlama, C.; Murphy, R. Emerging role of integrase inhibitors in the management of treatment - experienced patients with HIV infection. Ther. Clin. Risk Manag. 2009, 5, 331-340.
9. Beck-Engeser, G.B.; Eilat, D.; Harrer, D.; Jäck, H.-M.; Wabl, M. Early onset of autoimmune disease by the retroviral integrase inhibitor raltegravir. Proc. Natl. Acad. Sci. USA 2009 106, 20865-20870.
10. Williams, N.H.; Takasaki, B.; Wall, M.; Chin, J. Structure and nuclease activity of simple dinuclear metal complexes: Quantitative dissection of the role of metal ions. Acc. Chem. Res. 1999, 32, 485-493.
11. Beese, L.S.; Steitz, T.A. Structural basis for the 3′-5′ exonuclease activity of Escherichia coli DNA polymerase I: a two metal ion mechanism. EMBO J. 1991, 10, 25-33.
12. Goldgur, Y.; Dyda, F.; Hickman, A.B.; Jenkins, T.M.; Craigie, R.; Davies, D.R. Three new structures of the core domain of HIV-1 integrase: an active site that binds magnesium. Proc. Natl. Acad. Sci. USA 1998, 95, 9150-9154.
13. Lins, R.D.; Adesokan, A.; Soares, T.A.; Briggs, J.M. Investigations on human immunodeficiency virus type 1 integrase/DNA binding interactions via molecular dynamics and electrostatics calculations. Pharmacol. Therapeut. 2000, 55, 123-131.
14. Mekouar, K.; Mouscadet, J.-F.; Desmaele, D.; Subra, F.; Savoure, D.; Auclair, C.; d'Angelo, J. Styrylquinoline derivatives: a new class of potent HIV-1-integrase inhibitors that block HIV-1 replication in CEM cells. J. Med. Chem. 1998, 41, 2846-2857.
15. Meek, W.H.; Fuschman, C.H. Carboxylation of substituted phenol in N,N-dimethylamide solvents at atmospheric pressure; J. Chem. Eng. Data 1969, 14, 388-391.
16. Baret, P.; Béguin, C.G.; Boukhala, H.; Caris, C.; Laulhère, J.-P.; Pierre, J.-L.; Serratrice, G. OTRENSOX: A promising water-soluble iron chelator (Both FeIII and FeII) potentally suitable for plant nutrition and iron chelation therapy. J. Am. Chem. Soc. 1995, 117, 9760-9761.
17. Guo, W.; Li, J.; Fan, N.; Wu, W.; Zhou, P.; Xia, C. A simple and effective method for chemoselective esterification of phenolic acids. Synth. Commun. 2005, 35, 145-152.
18. Benard, C.; Zouhiri, F.; Normand-Bayle, M.; Danet, M.; Desmaele, D.; Leh, H.; Mouscadet, J.-F.; Mbemba, G.; Thomas, C.-M.; Bonnenfant, S.; Le Bret, M.; d'Angelo, J. Linker-Modified Quinoline Derivatives Targeting HIV-1 Integrase: Synthesis and Biological Activity. Bioorg. Med. Chem. Lett. 2004, 14, 2473-2476.
19. Desmaele, D.; Zouhiri, F. Unpublished Results.
20. Polanski, J.; Niedbala, H.; Musiol, R.; Podeszwa, B.; Tabak, D.; Palka, A.; Mencel, A. Finster, J.; Mouscadet, J.-F.; Le Bret, M. Fragment based approach for the investigation of HIV-1 integrase inhibition. Lett. Drug Des. Discovery 2007, 4, 99-105.
21. Polanski, J.; Niedbala, H.; Musiol, R.; Podeszwa, B.; Tabak, D.; Palka, A.; Mencel, A.; Finster, J.; Mouscadet, J.-F.; Le Bret, M. 5-hydroxy-6-quinaldic acid as a novel molecular scaffold for HIV-1 integrase inhibitors. Lett. Drug Des. Discovery 2006, 3, 175-178.
22. Zhuang, L.; Wai, J.S.; Embrey, M.W.; Fisher, T.E.; Egbertson, M.S.; Payne, L.S.; Guare, J.P., Jr.; Vacca, J.P; Hazuda, D.J.; Felock, P J.; Wolfe, A.L.; Stillmock, K.A.; Witmer, M.V.; Moyer, G.; Schleif, W.A.; Gabryelski, L.J.; Leonard, Y.M.; Lynch, J.J., Jr.; Michelson, S.R.; Young, S.D. Design and synthesis of 8-hydroxy-[1,6]naphthyridines as novel inhibitors of HIV-1 integrase in vitro and in infected cells. J. Med. Chem. 2003, 46, 453-456.
23. Guare, J.P.; Wai, J.S.; Gomez, R.P.; Anthony, N.J.; Jolly, S.M.; Cortes, A.R.; Vacca, J.P.; Felock, P.J.; Stillmock, K.A.; Schleif, W.A.; Moyer, G.; Gabryelski, L.J.; Jin, L.X.; Chen, I.W.; Hazuda, D.J.; Young, S.D. A series of 5-aminosubstituted 4-fluorobenzyl-8-hydroxy-[1,6]naphthyridine-7- carboxamide HIV-1 integrase inhibitors. Bioorg. Med. Chem. Lett. 2006, 16, 2900-2904.
24. Lee, J.Y.; Park, J.H.; Lee, S.J.; Park, H.; Lee, Y.S. Styrylquinazoline derivatives as HIV-1 integrase inhibitors. Arch. Pharm. 2002, 335, 277-282.
25. Polanski, J.; Zouhiri, F.; Jeanson, L.; Desmaele, D.; d'Angelo, J.; Mouscadet, J. F.; Gieleciak, R.; Gasteiger, J.; Le Bret, M. Use of the Kohonen neural network for rapid screening of ex vivo antiHIV activity of styrylquinolines. J. Med. Chem. 2002, 45, 4647-4654.
26. Zouhiri, F.; Mouscadet, J.-F.; Mekouar, K.; Desmaële, D.; Savouré, D.; Leh, H.; Subra, F.; Le Bret, M.; Auclair, C.; d'Angelo, J. Structure-activity relationships and binding mode of Styrylquinolines as potent inhibitors of HIV-1-integrase and replication of HIV-1 in cell culture. J. Med. Chem. 2000, 43, 1533-1540.
27. Yoo, H.; Lee, J.Y.; Park, J.H.; Chung, B.Y.; Lee, Y.S. Synthesis of styrylbenzofuran derivatives as styrylquinoline analogues for HIV-1 integrase inhibitors. Farmaco 2003, 58, 1243-1250.
28. Pearson, D.E.; Wysong, R.D.; Breder, C.V.J. The ortho bromination of phenols. J. Org. Chem. 1967, 32, 2358-2360.
29. Bookser, B.C. 2-Benzyloxymethyl-5-(tributylstannyl)tetrazole. A reagent for the preparation of 5- aryl- and 5-heteroaryl-1H-tetrazoles via the Stille reaction. Tetrahedron Lett. 2000, 41, 2805-2809.
30. Normand-Bayle, M. Synthesè et activité biologique de nouvelles styrylquinoleines inhibitrices de l'intégrase du VIH-1. Ph.D. Dissertation, Université Paris-Sud : Paris, France, 2007.
31. Espeseth, A.S.; Felock, P.; Wolfe, A.; Witmer, M.; Grobler, J.; Anthony, N.; Egbertson, M.; Melamed, J.Y.; Young, S.; Hamill, T.; Cole, J.L.; Hazuda, D.J. Proc. Natl. Acad. Sci. USA 2000, 97, 11244-11249.
32. Zouhiri, F.; Desmaele, D.; d'Angelo, J.; Ourevitch, M.; Mouscadet, J.-F.; Leh, H.; Le Bret, M. HIV-1 replication inhibitors of the styrylquinoline class: incorporation of a masked diketo acid pharmacophore. Tetrahedron Lett. 2001, 42, 8189-8192.
33. Normand-Bayle, M.; Bénard, C.; Zouhiri, F.; Mouscadet, J.-F.; Leh, H.; Thomas, C.-M.; Mbemba, G.; Desmaele, D.; d'Angelo, J. New HIV-1 replication inhibitors of the styryquinoline class bearing aroyl/acyl groups at the C-7 position: Synthesis and biological activity. Bioorg. Med. Chem. Lett. 2005, 15, 4019-4022.
34. Zouhiri, F.; Danet, M.; Benard, C.; Normand-Bayle, M.; Mouscadet, J.-F.; Leh, H.; Thomas, C.-M.; Mbemba, G.; d'Angelo, J.; Desmaele, D. HIV-1 replication inhibitors of the styrylquinoline class: Introduction of an additional carboxyl group at the C-5 position of the quinoline. Tetrahedron Lett. 2005, 46, 2201-2205.
35. Michaut, M.; Monneret, C.; Soma, E.; Thibault, L.; Wermuth, C. Styrylquinolines, their process of preparartion and their therapeutic uses. PCT Int. Appl. WO/2010/010148 A1, 2010.
36. Zeng, C.; Niu, L.; Ping, D.; Zhong, R. Design and synthesis of 2-styrylquinoline-7-sulfonamide derivatives as potential HIV integrase inhibitors. Chin. J. Org. Chem. 2009, 29, 1105-1114.
37. Auclair, C.; Giethlen, B.; Michaut, M.; Monneret, C.; Soma, E.; Thibault, L.; Wermuth, C. Styrylquinolines, their process of preparartion and their therapeutic uses. PCT Int. Appl. WO/2010/010147 A1, 2010.
38. Chow, S.A.; Vincent, K.A.; Ellison, V.; Brown, P.O. Reversal of integration and DNA splicing mediated by integrase of human immunodeficiency virus. Science 1992, 255, 723-726.
39. Courcot, B.; Firley, D.; Fraisse, B.; Becker, P.; Gillet, J. M.; Pattison, P.; Chernyshov, D.; Sghaier, M.; Zouhiri, F.; Desmaele, D.; d'Angelo, J.; Bonhomme, F.; Geiger, S.; Ghermani, N.E. Crystal and electronic structures of magnesium(II), copper(II), and mixed magnesium(II)- copper(II) complexes of the quinoline half of styrylquinoline-type HIV-1 integrase inhibitors. J. Phys. Chem. 2007, B111, 6042-6050.
40. Ouali, M.; Laboulais, C.; Leh, H.; Gill, D.; Desmaele, D.; Mekouar, K.; Zouhiri, F.; d'Angelo, J.; Auclair, C.; Mouscadet, J.-F.; Le Bret, M. Modeling of the inhibition of retroviral integrases by styrylquinoline derivatives. J. Med. Chem. 2000, 43, 1949-1957.
41. Ouali, M.; Laboulais, C.; Leh, H.; Gill, D.; Xhuvani, E.; Zouhiri, F.; Desmaele, D.; d'Angelo, J.; Auclair, C.; Mouscadet, J.-F.; Le Bret, M. Tautomers of styrylquinoline derivatives containing a methoxy substituent: computation of their population in aqueous solution and their interaction with RSV integrase catalytic core. Acta Biochim. Pol. 2000, 47, 11-22.
42. Ma, X.-h.; Zhang, X.-y.; Tan, J.-j.; Chen, W;-z; Wang, C.-x. Exploring binding mode for styrylquinoline HIV-1 integrase inhibitors using comparative molecular field analysis docking studies. Acta Pharmacol. Sin. 2004, 25, 950-958.
43. Firley, D.; Courcot, B.; Gillet, J.M.; Fraisse, B.; Zouhiri, F.; Desmaele, D.; d'Angelo, J.; Ghermani, N.E. Experimental/theoretical electrostatic properties of a styrylquinoline-type HIV-1 integrase inhibitor and its progenitors. J. Phys. Chem. B 2006, 110, 537-547.
44. Deprez, E.; Barbe, S.; Kolaski, M.; Leh, H.; Zouhiri, F.; Auclair, C.; Brochon, J.-C.; Le Bret, M.; Mouscadet, J.-F. Mechanism of HIV-1 integrase inhibition by styrylquinoline derivatives in vitro. Mol. Pharmacol. 2004, 65, 85-98. (Pubitemid 38113889)
45. Jenkins, T.M.; Esposito, D.; Engelman, A.; Craigie, R. Critical contacts between HIV-1 integrase and viral DNA identified by structure-based analysis and photo-crosslinking. EMBO J. 1997, 16, 6849-6859.
46. Esposito, D.; Craigie, R. Sequence specificity of viral end DNA binding by HIV-1 integrase reveals critical regions for protein-DNA interaction. EMBO J. 1998, 17, 5832-5843.
47. Harper, A.L.; Skinner, L.M.; Sudol, M.; Katzman, M. Use of patient-derived human immunodeficiency virus type 1 integrases to identify a protein residue that affects target site selection. J. Virol. 2001, 75, 7756-7762.
48. Perryman, A.L.; McCammon, J.A. AutoDocking dinucleotides to the HIV-1 integrase core domain: exploring possible binding sites for viral and genomic DNA. J. Med. Chem. 2002, 45, 5624-5627.
49. Hazuda, D.J.; Felock, P.; Witmer, M.; Wolfe, A.; Stillmock, K.; Grobler, J.A.; Espeseth, A.; Gabryelski, L.; Schleif, W.; Blau, C.; Miller, M.D. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000, 287, 646-650.
50. Bonnenfant, S.; Thomas, C.M.; Vita, C.; Subra, F.; Deprez, E.; Zouhiri, F.; Desmaele, D.; d'Angelo, J.; Mouscadet, J.-F.; Leh, H. Styrylquinolines, integrase inhibitors acting prior to integration: a new mechanism of action for anti-integrase agents. J. Virol. 2004, 78, 5728-5736.
51. Mousnier, A.; Leh, H.; Mouscadet, J.-F.; Dargemont, C. Nuclear import of HIV-1 integrase is inhibited in vitro by styrylquinoline derivatives. Mol. Pharmacol. 2004, 66, 783-788. (Pubitemid 39319449)
52. Malet, I.; Delelis, O.; Valantin, M.-A.; Montes, B.; Soulie, C.; Wirden, M.; Tchertanov, L.; Peytavin, G.; Reynes, J.; Mouscadet, J.-F.; Katlama, C.; Calvez, V.; Marcelin, A.-G. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob. Agents Chemother. 2008, 52, 1351-1358.
53. Delelis, O.; Thierry, S.; Subra, F.; Simon, F.; Malet, I.; Alloui, C.; Sayon, S.; Calvez, V.; Deprez, E.; Marcelin, A.-G.; Tchertanov, L.; Mouscadet, J.-F. Impact of Y143 HIV-1 integrase mutations on resistance to raltegravir in vitro and in vivo. Antimicrob. Agents Chemother. 2010, 54, 491-501.
54. Dvorin, J.D.; Bell, P.; Maul, G.G.; Yamashita, M.; Emerman, M.; Malim, M.H. Reassessment of the roles of integrase and the central DNA flap in human immunodeficiency virus type 1 nuclear import. J. Virol. 2002, 76, 12087-12096.
55. Thibault, L.; Rochas, S.; Dourlat, J.; Monneret, C.; Carayon, K.; Deprez, E.; Mouscadet, J.F.; Soma, E.; Lebel-Binay, S. New integrase binding inhibitors acting in synergy with raltegravir. Antivir. Ther. 2009, 14, A29, abstract 27.